Immunotherapy Shows 71% Complete Response Rate in Rare Melanoma Subtype
Pembrolizumab achieved remarkable 71% pathological complete response in desmoplastic melanoma patients before surgery.
6520 articles
Pembrolizumab achieved remarkable 71% pathological complete response in desmoplastic melanoma patients before surgery.
Researchers found that stopping HER2 protein degradation significantly improves trastuzumab deruxtecan cancer treatment outcomes.
Scientists discover how to make aggressive triple-negative breast cancer vulnerable to existing targeted therapy.
New research reveals how a rare form of melanoma responds exceptionally well to cutting-edge immunotherapy treatments.
Researchers analyzed 1,294 blood samples to create a comprehensive cancer detection method using cell-free DNA patterns.
New research reveals behavioral interventions may help some aspects of oral hygiene in periodontal disease patients, but evidence remains uncertain.
New research protocol examines whether anabolic drugs can improve rehabilitation outcomes after hip fractures in elderly patients.
New review reveals cancer vaccines work better alongside checkpoint inhibitors, offering hope for personalized treatment.
Researchers discovered specific cell markers that predict which leukemia patients will achieve lasting remission from CAR-T therapy.
Scientists discover cancer-specific RNA molecules in blood that could revolutionize early detection and monitoring.
Researchers mapped cancer surface proteins across 85 patient samples, identifying FAT2 as a promising target for CAR-T cell therapy.
Stanford researchers create comprehensive database showing how maternal diet, microbiome, and medications affect fetal development.